GlaxoSmithKline shares jumped 3 percent after the U.K.-listed pharmaceutical giant reported second-quarter earnings per share that were slightly higher than forecast on Wednesday.» Read More
U.S. producer prices rose more slowly than expected in October despite a rebound in food and energy costs, according to a report on Tuesday. Bruce Kasman, chief U.S. economist at JPMorgan, shared his view.
Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies.
You know that Tim Seymour is bullish on China but now he’s got three new reasons to get long. Should you follow any of them?
GlaxoSmithKline is one of the handful of drug companies on the front lines of the fight against the flu. In fact, it is the only company that has products on both sides. GSK makes a vaccine and an antiviral. In the third quarter, GSK today reported that it sold nearly $300 million worth of the inhalable flu-fighter Relenza. That’s a more than 10-fold increase from a year ago. And CEO Andrew Witty reportedly forecast around $1.6 billion worth of flu shot sales in the fourth quarter.
Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report. Travelers and MMM led the Dow.
Swiss drug giant Novartis says it has redeployed 300 workers from other divisions into its vaccines unit to meet what Chairman and CEO Dr. Daniel Vasella calls the "huge demand" for H1N1 shots.
Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report.
Stocks slipped Thursday as investors weighed a disappointing jobless-claims report and some encouraging earnings reports.
Earnings continue to come in largely above expectations, but other factors are waylaying the stock market's recent advances - ranging from Walmart's price cuts to analyst Richard Bove's downgrade of Wells Fargo to rising oil prices.
With Amgen dropping after hours and Merck, Celgene and others reporting earnings on Thursday, how should you game health care?
In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.
This Friday the CDC is expected to start giving weekly updates on where and how much H1N1 vaccine has been shipped. I'm curious what the demand will truly turn out to be. Some people are growing concerned about the increasing number of pediatric deaths from H1N1 and may rush to get their kids and themselves vaccinated. Others are afraid of or paranoid about the vaccine.
Vanda Pharmaceuticals may go down in industry history as one of the most remarkable turnaround stories.
Dow component Johnson & Johnson—the first major health care company to report earnings this quarter—posted weaker-than-expected quarterly revenue on Tuesday. Mike Weinstein, managing director and senior medical technology analyst at JPMorgan, offered his analysis of JNJ.
Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.
The CDC announced today that healthcare workers in Tennessee and Indiana would be amongst the first to get swine flu vaccinations. The outbreak of the H1N1 swine flu virus has sadly killed over 3,900 peope per a report by the World Health Organization (WHO) on September 25th. At the same time the race to battle the pandemic has propped up the shares of biotech companies that promise solutions.
The number-one H1N1 flu concern among U.S. businesses is the availability of a vaccine for employees, according to a new survey by the Business Roundtable.
Major US companies are bracing for a potentially stronger strain of swine flu this year that could threaten the nation's already fragile economic recovery.
The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.
So far, it hasn't been a September to remember on Wall Street. With three days in the books, the month is living up to its historic billing as the worst month of the year for stock investors, though Wednesday's losses were relatively small. Read and listen to what the pros had to say...